Cytomegalovirus (CMV) Infection Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - Estimates DelveInsight | Moderna, Nobelpharma, Biotest, AlloVir, Merck, Chimerix, VBI Vaccines, SpyBiotech, MEMO Therapeutics, Lion TCR

DelveInsight's "Cytomegalovirus (CMV) Infection Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Cytomegalovirus (CMV) Infection market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Cytomegalovirus (CMV) Infection, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Cytomegalovirus (CMV) Infection, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Cytomegalovirus (CMV) Infection management.

Learn How the Cytomegalovirus (CMV) Infection Market is Evolving with the Ongoing Developments @ Cytomegalovirus (CMV) Infection Market Outlook

Cytomegalovirus (CMV) Infection: An Overview

Cytomegalovirus (CMV) Infections is a type of herpesvirus (herpesvirus type 5) with a wide range of symptoms: from no symptoms to fever and fatigue (resembling infectious mononucleosis) to severe symptoms involving the eyes, brain, or other internal organs. It is a common virus for people of all ages; however, a healthy person’s immune system usually keeps the virus from causing illness. Blood tests show that 60–90% of adults have had a CMV Infections infection at some time.

CMV Infections may cause symptoms soon after infection, and can also remain dormant (inactive) in various tissues for life. Various stimuli can reactivate the dormant CMV Infections, resulting in virus growth, which can sometimes cause disease. The lungs, gastrointestinal tract, brain, spinal cord, or eyes may be infected.

When the infection threatens life or eyesight, an antiviral drug (valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination) may be given. These drugs may be given by mouth or by vein. When CMV Infections retinitis is very severe, the drugs may also be injected directly into the eye. These drugs have serious side effects, which increase the demand and need for more potential therapies.

Cytomegalovirus (CMV) Infection Market Key Facts

• In 2022, the total diagnosed cases of CMV were found out to be 111,100+ in the 7MM. These cases are expected to increase by 2032. It was also found that 40% of solid organ transplant patients are diagnosed with CMV in the US.
• Among the European countries, France had the highest diagnosed cases of CMV with 8,800+ cases, followed by the UK which had a diagnosed population of 7,400+ in 2022. On the other hand, Italy had the lowest diagnosed incident population of 3,800+ in 2022.
• In 2022, a total of 3,100+ incident population of HSCT was estimated in Germany. These cases are further expected to increase. DelveInsight also estimates that the number of CMV patients from HSCT patients are found out to be 1,100+ in 2022 in Germany.
• Japan had 7,200+ diagnosed cases of CMV in 2022, which is expected to increase during the forecast period.
• According to DelveInsight, CMV Infections affects males and female equally.

Get Exclusive Data and Key Insights Shaping the Market Dynamics @ Cytomegalovirus (CMV) Infection Market Trends

Cytomegalovirus (CMV) Infection Therapeutics Analysis

CMV infection or reactivation can lead to serious complications in hosts whose immune systems are either compromised by disease or suppressed, which is common following stem cell and solid organ transplants. The treatment market for CMV infections is divided into Prophylactic and Therapeutic Drugs.

Prophylactic Management: Transmission of cytomegalovirus is often preventable because it is most often transmitted through infected bodily fluids that come in contact with hands and then are absorbed through the nose or mouth of a susceptible person. There are two major strategies for CMV disease prevention after liver transplantation that include preemptive therapy and antiviral prophylaxis.

For preemptive therapy, patients are monitored for evidence of CMV replication by sensitive assays, most commonly using quantitative nucleic acid amplification tests by PCR and less commonly by detection of pp65 antigenemia, and upon the detection of asymptomatic CMV replication, antiviral therapy is administered preemptively to prevent progression to symptomatic clinical disease.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Cytomegalovirus (CMV) Infection. Currently, Moderna is leading the therapeutics market with its Cytomegalovirus (CMV) Infection drug candidates in the most advanced stage of clinical development.

Cytomegalovirus (CMV) Infection Therapeutic Advancements and Emerging Treatments:

• Cytomegalovirus (CMV) Infection Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others, are actively engaged in developing novel drugs for potential market entry.
• Cytomegalovirus (CMV) Infection Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Cytomegalovirus (CMV) Infection. Some of the emerging therapies in the pipeline include mRNA-1647 (Moderna), Posoleucel (AlloVir), SYN002 (Synklino), and others.

Recent Developments in the Cytomegalovirus (CMV) Infection Market

• On June 06, 2023, Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for PREVYMIS® (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]) following a priority review.
• On November 11, 2022, Takeda (TSE:4502/NYSE: TAK) announced that the European Commission (EC) has granted Marketing Authorization for LIVTENCITYTM (maribavir) for the treatment of cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the Cytomegalovirus (CMV) Infection Market

Cytomegalovirus (CMV) Infection Market Growth Factors and Associated Trends

The market landscape for Cytomegalovirus (CMV) infection presents a complex interplay of several drivers and barriers shaping the development and accessibility of treatments. Among the key drivers is the increasing recognition of CMV as a significant cause of morbidity and mortality in immunocompromised individuals, such as transplant recipients and those living with HIV/AIDS. This recognition has spurred research efforts focused on developing antiviral therapies targeting CMV, driving innovation in treatment strategies. Additionally, advancements in diagnostic technologies, including more sensitive and specific assays for CMV detection, have improved early identification and management of the infection. Moreover, the expanding aging population, where CMV poses severe risks, particularly in pregnant women and neonates, emphasizes the need for effective preventive and therapeutic interventions.

However, several barriers impede progress in the CMV infection market. Limited treatment options with potential adverse effects and the emergence of drug-resistant strains pose significant challenges. Furthermore, the complexities of CMV's pathogenesis and its ability to establish latent infections, evading the immune response, complicate the development of vaccines and therapeutics. The high costs associated with the research and development of antiviral agents, coupled with stringent regulatory requirements for drug approval, hinder the introduction of novel treatments. Accessibility and affordability issues, particularly in low- and middle-income regions, limit the availability of effective therapies and preventive measures.

Addressing these barriers necessitates concerted efforts in research, innovation, and collaboration among pharmaceutical companies, healthcare providers, and public health organizations. Advancements in understanding CMV's biology, coupled with the development of targeted antiviral therapies and vaccines, can potentially mitigate the impact of CMV infections and improve outcomes for vulnerable populations affected by this widespread viral infection.

Cytomegalovirus (CMV) Infection Market

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Cytomegalovirus (CMV) Infection. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Cytomegalovirus (CMV) Infection market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Cytomegalovirus (CMV) Infection drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Cytomegalovirus (CMV) Infection Therapeutics Market Forecast

Cytomegalovirus (CMV) Infection Epidemiology Assessment

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Cytomegalovirus (CMV) Infection epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Cytomegalovirus (CMV) Infection epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Cytomegalovirus (CMV) Infection Epidemiology, Segmented as -

• Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the 7MM [2019–2032]
• Number of Infants born with Congenital CMV in the 7MM [2019–2032]
• Number of CMV Patients among SOT in the 7MM [2019–2032]
• CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the 7MM [2019–2032]
• CMV Retinitis among HIV Patients in the 7MM [2019–2032]
• Number of Refractory CMV Patients after HSCT/SOT in the 7MM [2019–2032]

Cytomegalovirus (CMV) Infection Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Cytomegalovirus (CMV) Infection market during the study period. This analysis encompasses the assessment of drug uptake in the Cytomegalovirus (CMV) Infection market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Cytomegalovirus (CMV) Infection drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Cytomegalovirus (CMV) Infection pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Cytomegalovirus (CMV) Infection. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

Reports Key Features and Analysis

• Study Period - 2019-32
• Forecast Period - 2023-32
• Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
• Market Size (by 2032) and Expected CAGR - Download the Sample PDF
• Major Players Shaping the Market Outlook - Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others.
• Emerging and Marketed Therapies Analyzed in the Report - mRNA-1647 (Moderna), Posoleucel (AlloVir), SYN002 (Synklino), and many others.

For In-depth Insights, key Report Offerings TOC, Access the Sample PDF File @ Cytomegalovirus (CMV) Infection Therapeutics Market Outlook and Forecast

Related Reports:

• Cytomegalovirus (CMV) Infection Epidemiology Forecast

Cytomegalovirus (CMV) Infection Epidemiology Forecast report delivers an in-depth understanding of the Cytomegalovirus (CMV) Infection, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• Cytomegalovirus (CMV) Infection Pipeline Insight

Cytomegalovirus (CMV) Infection Pipeline Insight report, provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the Cytomegalovirus (CMV) Infection therapetuic landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case Study!

Healthcare Consulting and Market Research Services by DelveInsight

Unlock key insights and innovation in the healthcare industry with our cutting-edge market research services, paving the way for informed decisions and competitive advantage in this rapidly evolving industry @ Medical Device Consulting Services

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

 Contact Information:

Shruti Thakur (Manager, Marketing and IB)

info@delveinsight.com

www.delveinsight.com

Connect with DelveInsight: LinkedIn | Facebook | Twitter